GTF2B

Across TCGA pan-cancer cohorts, GTF2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GTF2B data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GTF2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GTF2B expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where GTF2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	1.000	0.690	.001	33	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	11	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →
UCEC	DFS	Tertile	All	0.933	0.758	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GTF2B–LSCC (OS)

Open the LSCC breakdown →